Introduction
Switzerland’s patent system hasn’t changed fundamentally in a generation. The Swiss Patent Act — governing domestic Swiss patents administered by the Federal Institute of Intellectual Property (IPI) — has operated largely unchanged while the surrounding European patent environment evolved significantly around it. The UPC launched. The CJEU issued cross-border injunction rulings. The EPO’s examination standards evolved. Swiss patent law stayed relatively still.
That’s changing. In March 2024, the Swiss Parliament adopted a partial revision of the Patent Act — the most significant update to Swiss domestic patent law in decades. The Federal Council submitted the fully revised Patent Ordinance for consultation in April 2025. The Federal Council is expected to approve the revised Ordinance in May 2026, with an anticipated effective date of January 1, 2027.
For companies operating in Switzerland’s most patent-intensive sectors — pharmaceuticals, medical technology, watchmaking, precision instruments, and specialty chemicals — the reform changes both what Swiss patent protection can achieve and what the competitive IP landscape looks like. This article covers the two changes that matter most for landscape strategy, the actions to take before the window closes, and what the post-reform Swiss patent environment will look like for each major sector.
What the Swiss Patent Act Revision Actually Changes
Two changes are operationally significant for patent landscape analysis and competitive IP strategy. The rest of the revision covers procedural clarifications and administrative updates that matter primarily to prosecution counsel.
Change 1: Protection Scope Aligned with EPO Standards
Current Swiss domestic patents operate under a slightly different protection scope standard than EPO-granted European patents validated in Switzerland. The difference is subtle but material in technology sectors where claim scope is commercially decisive — particularly pharmaceutical compound claims and medtech device claims where the boundary between infringing and non-infringing products is narrow.
The revised Act aligns Swiss patent protection scope with EPO standards. Swiss domestic patents will offer protection comparable to European patents for the first time — removing a long-standing asymmetry that has affected how Swiss domestic patents are valued relative to their European counterparts and how they factor into competitive landscape analysis.
For landscape analysis, this means the protection scope of Swiss domestic patents needs to be assessed using the EPO-comparable standard from January 2027 onwards. Patents that appeared narrower under the current Swiss standard may carry materially broader protection scope under the revised Act. Competitive landscapes built before the reform may underweight the scope of Swiss domestic patents held by competitors.
Current Swiss standard: Swiss domestic patents assessed under Swiss-specific protection scope standard. Slight asymmetry with EPO-granted European patents validated in Switzerland.
Post-2027 standard: Swiss domestic patents assessed under EPO-comparable scope standard. Protection coverage aligned with European patents. The asymmetry is removed.
Change 2: IPI Opposition Procedure Abolished — Direct FPC Appeals
The IPI currently offers an administrative opposition procedure for challenging granted Swiss domestic patents within 9 months of grant — a relatively accessible, lower-cost mechanism compared to Federal Patent Court nullity proceedings. Under the revised Act, this administrative opposition procedure is abolished. Validity challenges go directly to the Swiss Federal Patent Court.
The consequences for the competitive IP landscape are specific:
- Weaker patents that would previously have been administratively opposed may survive longer. The IPI opposition was a fast, relatively low-cost route to challenging questionable Swiss domestic patents within 9 months of grant. Without it, marginal patents that an administrative opponent would have challenged are more likely to go unchallenged — at least until a market entrant or competitor decides the commercial stakes justify full FPC nullity proceedings.
- The bar for validity challenges rises. FPC nullity proceedings are more expensive, more formal, and require more preparation than IPI opposition proceedings. The practical consequence: fewer validity challenges will be filed against Swiss domestic patents post-reform, and those that are filed will be by parties with serious commercial stakes in the outcome.
- Swiss domestic patents become more defensively robust. A patent that survives in an environment where opposition is easier is a weaker signal of validity than one that survives where challenges are harder. Post-reform, a granted Swiss domestic patent that hasn’t been challenged carries a stronger presumption of validity — at least in practice.
Why Switzerland Matters as a Patent Jurisdiction
Switzerland is consistently ranked the world’s most innovative country. For European pharma innovators and IP strategists, Switzerland isn’t a secondary jurisdiction to monitor from a distance — it’s the home base of some of the world’s most commercially significant patent portfolios. Novartis, Roche, Lonza, Straumann, Sonova, and dozens of specialty pharma and medtech companies operate from Swiss IP foundations.
The Swiss patent landscape has two layers that together define the full IP picture: EPO-granted European patents validated in Switzerland (subject to the Swiss FPC, enforceable under Swiss law) and domestic Swiss patents granted by the IPI (a separate right, not equivalent to a validated European patent). Most competitive IP analysis focuses on the EPO layer and underweights the domestic Swiss patent layer. The reform’s scope alignment change makes that asymmetry more significant — post-reform, domestic Swiss patents carry protection comparable to their EPO counterparts. Ignoring the domestic layer means missing a material portion of the competitive IP picture.
How the Revision Changes Patent Landscape Analysis for the Swiss Market
The practical implication of the revision for patent landscape analysis is threefold.
The opposition abolition changes the landscape’s validity signals. In the current system, Swiss domestic patents that were filed and granted in the last decade had a 9-month window during which any party could file an administrative opposition. The absence of opposition during that window provides some signal — however imperfect — that the patent wasn’t considered sufficiently vulnerable to challenge. Post-reform, that signal disappears. All Swiss domestic patents granted after January 2027 will be unchallenged by default, not because they’re strong but because the low-cost challenge mechanism no longer exists. Landscape analysis of post-reform Swiss patents needs to factor in that the absence of challenge is less meaningful than it was under the current system.
Stronger protection scope changes competitive risk weighting. EPO-comparable scope means the Swiss domestic patents in your landscape may cover a broader range of competitive products than the current scope standard suggests. For competitive landscape analysis — particularly in pharma and medtech where product-to-claim mapping is central — the post-reform scope standard needs to be applied to identify the true competitive IP exposure from Swiss domestic patent holders.
The IPI opposition window is a now-or-never opportunity. For competitor patents that are currently within the 9-month IPI opposition window and that have validity vulnerabilities, the window closes permanently when the revised Act takes effect. Any Swiss domestic patent that could be challenged through IPI opposition needs to be identified and assessed before January 2027. After that date, the same challenge requires full FPC nullity proceedings — significantly more resource-intensive.
The Window That’s Closing: Act Before January 2027
The Federal Council is expected to approve the revised Ordinance in May 2026. That gives companies operating in the Swiss market approximately 7 months to act under the current rules before the revised Act takes effect. Here are the four actions that have a time-critical dimension:
Action 1: File IPI Opposition on Competitor Patents Now — Identify Swiss domestic patents held by competitors in your technology space that were granted within the last 9 months. Assess each for validity vulnerabilities. File IPI opposition on any patent that (a) poses a genuine competitive threat and (b) has a credible invalidity argument. After January 2027, this option is gone permanently. What previously required a relatively accessible administrative filing will require full FPC nullity proceedings.
Action 2: Review Pending Swiss Applications for Scope Alignment — For pending Swiss domestic patent applications, assess whether the claims are drafted to take full advantage of the EPO-comparable scope standard that will apply post-reform. Claims drafted under the current Swiss-specific standard may be narrower than the revised Act would permit. Applications still in prosecution may benefit from claim adjustments before the reform takes effect.
Action 3: Run a Pre-Reform Landscape of the Swiss Market — Commission a landscape analysis of the Swiss domestic patent space in your technology area before January 2027. This captures both the current protection scope of competitor patents and the IPI opposition history — which provides validity signals that will no longer be generated post-reform. The pre-reform landscape is a different document from the post-reform landscape, and both have distinct strategic value.
Action 4: Plan Swiss Market Entry Around the New Protection Standards — For companies planning Swiss market entry after January 2027, factor in that the domestic Swiss patents you’ll face carry EPO-comparable protection scope and are significantly less likely to have been validity-challenged than pre-reform patents. FTO analysis for post-reform Swiss market entry needs to account for the stronger protection standard.
Sector-Specific Implications: Pharma, MedTech, and Precision Technology
The reform’s practical impact isn’t uniform across Switzerland’s innovation sectors. Here’s how it plays out in the three most patent-intensive areas.
- Pharmaceuticals. Swiss pharmaceutical patents — particularly compound claims and formulation patents — are among the most commercially significant in the Swiss domestic patent register. The scope alignment change matters most here: EPO-comparable scope for Swiss compound claims may extend protection to a broader range of pharmaceutical products than the current Swiss standard. For generic manufacturers and biosimilar developers planning Swiss market entry, the post-reform scope standard needs to be assessed for every blocking patent in the FTO analysis. SPC extensions are unaffected by the reform, but the underlying patent’s scope may change.
- Medical technology. Swiss medtech companies — Straumann in dental implants, Sonova in hearing instruments, Ypsomed in drug delivery devices — hold significant domestic Swiss patent portfolios covering device designs, manufacturing processes, and software-integrated systems. The post-reform scope alignment means these portfolios may carry broader protection than their current Swiss-specific scope suggests. For international medtech companies selling into Switzerland, the FTO picture for post-reform Swiss domestic patents needs to be assessed under the new standard.
- Precision technology and watchmaking. Switzerland’s watchmaking and precision instrument industry has a deep patent history in mechanical systems, materials, and manufacturing processes. The opposition abolition is particularly relevant here — many precision technology patents are filed by smaller companies that relied on the IPI opposition as a cost-effective mechanism for managing competitive validity challenges. Post-reform, the landscape in this sector may become less contested, with weaker patents surviving longer simply because the low-cost challenge mechanism no longer exists.
How Our Landscape Analysis Service Covers the Swiss Market
Our patent landscape analysis covers both layers of the Swiss IP landscape — EPO-granted European patents validated in Switzerland and domestic Swiss patents registered with the IPI — giving a complete picture of the competitive IP environment in any Swiss technology sector.
For companies with time-critical actions before January 2027, we structure engagements specifically around the IPI opposition window: identifying competitor patents within the 9-month opposition period, assessing validity vulnerabilities, and recommending action on patents that warrant pre-reform challenge. For companies planning post-2027 Swiss market entry, we provide landscape analysis applying the EPO-comparable scope standard that will govern the post-reform environment. The pre-reform and post-reform Swiss landscapes are genuinely different documents — and understanding why patent landscape analysis is strategically essential to business decisions is the starting point for using both effectively.
Switzerland’s Patent Act revision changes the competitive IP landscape for pharma, medtech, and precision technology. The IPI opposition window closes permanently in January 2027. Our landscape analysis covers both layers of Swiss patent protection — and identifies the actions that need to happen before the window does. → Contact Us
Conclusion: The Takeaway
The Swiss Patent Act revision is a generation-level change to a patent system that hasn’t changed fundamentally in decades. EPO-comparable scope means Swiss domestic patents will carry broader protection than the current standard allows. The abolition of IPI opposition means weaker patents will face fewer challenges and survive longer. Both changes affect how the Swiss patent landscape should be read and acted upon.
The Federal Council is expected to approve the revised Ordinance in May 2026. The effective date is January 1, 2027. The window to act under the current rules — particularly for IPI opposition filings on competitor patents with validity vulnerabilities — is measured in months, not years. The companies that identify the patents worth challenging and file before the window closes are the ones that preserve competitive options that won’t be available under the revised Act.
The landscape is changing. The question is whether you understand the current landscape well enough to act on it before it does.
